PLUS news 11/03/2010
Retail-focused stock exchange PLUS has regaled investors again with news of upbeat trading volumes during January.
Global quoted biotechnology sales topped a staggering £35 billion
last year and the recent success within the sector is being reflected
in record merger and acquisition premiums, informs a new report
from Ernst & Young.
Sales from listed biotechnology ventures burgeoned by 14 per cent to $73.4 billion (£36.7 billion) in 2006, the global industry raised $27.9 billion (£14 billion), compared with $19.7 billion (£9.9 billion) in 2005 and venture capital funding for the sector hit an all-time high of $5.4 billion (£2.7 billion). These surging prices paid for assets, according to Ernst & Young, reflect biotechnology’s pivotal position within drug discovery.
Tellingly, the average takeover premium paid in transactions worth more than $500 million (£250 million) was 60 per cent last year, more than twice the average paid between 2003 and 2005. Pharma heavyweights such as Pfizer, GlaxoSmithKline and Novartis are looking to acquire biotechs to boost in-house drug pipelines as biotech firms often have the most promising know-how for developing new medicines. This means high levels of interest in early-stage platforms and technologies from pharmaceutical giants rather than in late-stage products.
Glen Giovannetti, Ernst & Young’s global biotechnology leader, said, ‘We now have widespread recognition among buyers of the potential value in biotech’s platforms and pipelines. The industry in the US has never been stronger and we’re seeing its success story spreading to other parts of the world, particularly Europe.’
The US remains the biotech industry hub, although Europe and Asia are growing fast. The European biotech sector bounced back in 2006 with its market capitalisation increasing 43 per cent to £42.3 billion, while the smaller Asia Pacific biotech sector has enjoyed strong 46 per cent revenue growth to $3 billion (£1.5 billion) over the past year. Ernst & Young forecasts that the global industry will achieve revenues of
$100 billion (£50 billion) before 2010.
£7,277 That’s what you would have in your portfolio if you had invested £6,000 into the six Company Watch recommendations in our April 2009 issue.
Advertisement
Free access to the latest AIM stock recommendations and news from the award-winning Growth Company Investor team. Receive our tips on what stocks to buy direct to your inbox every Tuesday and Friday. Find out more today.
Cautious? Positive? Adventurous? Choose between three levels of risk for a fund of funds from Sharefunds, our sister company. Click here for more information.
The brand new, fully updated AIM Guide 2009/2010 is now available to purchase. AIM Guide is the only fully comprehensive guide to AIM and is regarded as 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today and benefit from a £10 discount!
This report's principal aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest. Click here for more information.
Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy the Cash Shells 2009 Research Report today or email Halid Delkic to obtain a free two-page abstract.
In-depth coverage of selected AIM companies within the small-cap and fast growing company sector including AIM and PLUS Markets shares and listed stocks. Company research and analysis from GCI analysts updated daily.
Advertisement
Retail-focused stock exchange PLUS has regaled investors again with news of upbeat trading volumes during January.
The AIM All-Share index dipped and rose slightly but essentially failed to move much over the course of February, starting at 667.27 points and closing at 667.24 as the market took a breather.
Snowfall fails to help retail recovery